炬芯科技(688049.SH):公司智能錄音筆芯片已覆蓋科大訊飛、飛利浦和漢王等終端品牌
格隆匯4月27日丨有投資者在投資者互動平台向炬芯科技(688049.SH)提問,“請問貴公司為科大訊飛和漢王科技提供的智能語音交互芯片具體是什麼型號,大致能實現怎樣的功能,是否為上述兩家公司提供CHAT GPT語音輸入端側的硬件支持?”
炬芯科技回覆稱,公司的智能錄音筆芯片已覆蓋科大訊飛、飛利浦和漢王等終端品牌,主要提供智能語音前處理(高品質拾音降噪)、高品質音頻編解碼、本地錄音、無線傳輸等功能。公司的語音交互產品可作為與包括如百度智能雲、ChatGPT在內的雲端技術實現語音人機交互場景的端側入口。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.